Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Andreani et al., Microbial Pathogenesis, doi:/10.1016/j.micpath.2020.104228
Apr 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
In Vitro study showing that HCQ and AZ have a synergistic effect on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
Andreani et al., 25 Apr 2020, peer-reviewed, 11 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperHCQAll
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andreani, Marion Le Bideau, Isabelle Duflot, Priscilla Jardot, Clara Rolland, Manon Boxberger, Nathalie Wurtz, Jean-Marc Rolain, Philippe Colson, Bernard La Scola, Didier Raoult
Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
Author statement Virus culture and drug testing: JA, ML, ID, NW; Molecular biology testing: PJ, CR, MB; Analyzed the results: JA, JMR, PC, BL, DR; Wrote the manuscript: JA, BL; Conceived the study: BL, DR. Pictures were captured on ZEISS AxioCam ERC 5s, 58 h post infection. Magnitude X200.3A-B-C. overview of the monolayer in each well for the condition of azithromycin 5 μM associated with hydroxychloroquine at 5 μM, 3D. Negative control well and 3E. Positive control well. 1F. Observation was done 48 h post infection by the SARS-CoV 2 strain IHUMI-3 for the viral stock production. Magnitude X400. Declaration of competing interest Authors would like to declare that Didier Raoult is a consultant in microbiology for Hitachi High-Tech Corporation. Funding sources had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The others authors declare no conflict of interest.
Amrane, Tissot-Dupont, Doudier, Eldin, Hocquart et al., Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infections diseases referral hospital in Marseille, France, -January 31st to March 1st, 2020: a respiratory virus snapshot, Trav. Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101663
Armstrong, Richez, Raoult, Chabriere, Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease, J. Chromatogr. B Analyt Technol. Biomed. Life Sci
Bosseboeuf, Aubry, Nhan, De Pina, Rolain et al., Azithromycin inhibits the replication of Zika virus, J. Antivir. Antiretrovir
Boulos, Rolain, Raoult, Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells, Antimicrob. Agents Chemother
Chen, Lau, Lamirande, Paddock, Bartlett et al., Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection, J Virol
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int. J. Antimicrob. Agents
De Wilde, Jochmans, Posthuma, Zevenhoven-Dobbe, Van et al., Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int. J. Antimicrob. Agents
Fenollar, Puechal, Raoult, Whipple's disease, N. Engl. J. Med
Fleming-Dutra, Demirjian, Bartoces, Roberts, Taylor et al., Variations in antibiotic and azithromycin prescribing for children by geography and specialty-United States, 2013, Pediatr. Infect. Dis. J
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Keyaerts, Li, Vijgen, Rysman, Verbeeck et al., Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice, Antimicrob. Agents Chemother
Keyaerts, Vijgen, Maes, Neyts, Van, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun
Kn Lusamba, Nomura, Kawase, Ota, Kubo et al., The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells, Physiol Rep
Kn Lusamba, Nomura, Kawase, Ota, Kubo et al., The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells, Physiol Rep
Kono, Tatsumi, Imai, Saito, Kuriyama et al., Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK, Antivir. Res
Kruse, Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int. J. Antimicrob. Agents
Li, Zu, Deng, Li, Parvatiyar et al., Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses, Antimicrob. Agents Chemother, doi:10.1128/AAC.00394-19
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Livak, Schmittgen, Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods
Mf Morgene, Maurin, Pillet, Berthelot, Morfin et al., HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics, Virology
Morens, Folkers, Fauci, What is a pandemic?, J. Infect. Dis
Nabirothckin, Peluffo, Bouaziz, Cohen, Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19, doi:10.20944/preprints202003.0302.v1
Ohkuma, Poole, Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH various agents, Proc. Natl. Acad. Sci. U.S.A
Raoult, Drancourt, Vestris, Bactericidal effect of Doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells, Antimicrob. Agents Chemother
Raoult, Houpikian, Tissot-Dupont, Riss, Arditi-Djiane et al., Treatment of Q fever endocarditis : comparison of two regimens containing doxycycline and ofloxacin or hydroxychloroquine, Arch. Intern. Med
Retallack, Di, Arias, Knopp, Laurie et al., Zika virus cell tropism in the developing human brain and inhibition by azithromycin, Proc. Natl. Acad. Sci. U. S. A
Rothe, Schunk, Sothmann, Bretzel, Froeschl et al., Transmission of 2019-nCoV infection from an asymptomatic contact in Germany, N. Engl. J. Med
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect. Dis
Vabret, Dina, Gouarin, Petitjean, Tripey et al., Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France, J. Paediatr. Child Health
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Cui, Li, Gao, Yuan et al., Teicoplanin inhibits Ebola pseudovirus infection in cell culture, Antivir. Res
Zaki, Van, Bestebroer, Osterhaus, Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med
Zhang, Ma, Yu, Liu, Zou et al., Teicoplanin potently blocks the cell entry of 2019-nCoV, doi:10.1101/2020.02.05.935387
Zhu, Zhang, Wang, Li, Yang et al., A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop